Japan – Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China

0
2

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) revealed today that the internal found and established orexin receptor villain DAYVIGO ® (trademark name in China: “DAYVIGO ® “generic name: lemborexant) has actually released in China for the treatment of grownups with sleeping disorders, identified by problems with sleep start and/or sleep upkeep. Eisai got approval for DAYVIGO in China on May 27, 2025. This marks the very first orexin receptor villain to be introduced in China.

DAYVIGO is a double orexin receptor villain that hinders orexin neurotransmission managing sleep-wake rhythm by binding competitively to the 2 subtypes of orexin receptors(OX1R and OX2R ). Unlike traditional treatments such as benzodiazepines that act straight on drowsiness, DAYVIGO acts upon the orexin neurotransmitter system, which manages wakefulness. DAYVIGO is thought to help with sleep on set and sleep upkeep, and wake by managing sleep-wake rhythm by reducing hyper wakefulness. DAYVIGO binds to orexin receptors OX1R and OX2R and serves as a competitive villain with more powerful inhibition impact on OX2R, which reduces both REM and non-REM sleep drive, such that DAYVIGO might supply faster sleep beginning and much better sleep upkeep to clients.

Sleeping disorders is defined by trouble dropping off to sleep, remaining asleep, or both in spite of an appropriate chance to sleep, that has actually taken place a minimum of 3 times a week for a minimum of one month, and which can cause tiredness, problem focusing and irritation.1,2 The frequency of sleeping disorders amongst grownups in China is reported to be 15.0%3, with around 172.5 million individuals believed to experience sleeping disorders.4 Currently, the mainstream prescription drugs for sleeping disorders in China are treatments that act straight on drowsiness, and there is increasing need for brand-new treatment alternatives.

Eisai will provide unique action system, DAYVIGO, as a brand-new treatment alternative to Chinese sleeping disorders clients with the hope of adding to repair of daytime function and healing for clients with sleeping disorders by possibly providing an active daytime life through quick sleep start and excellent quality sleep.

“DAYVIGO ®” Product Outline

Chinese Trade name:(DAYVIGO)
Chinese generic name:(Lemborexant Tablets)
Indicator for usage: Insomnia in grownups that defined by problems with sleep beginning and/or sleep upkeep Dosage and administration: The advised dose of DAYVIGO is 5 mg taken when per night, right away before going to sleep, with a minimum of 7 hours staying before the organized time of awakening. The dosage might be increased to the optimum dosage of 10 mg.

About DAYVIGO (Generic Name: Lemborexant)

DAYVIGO, an orexin receptor villain, is Eisai’s internal found and established little particle that hinders orexin neurotransmission by binding competitively to the 2 subtypes of orexin receptors (orexin receptor 1 and 2). Quick on/off receptor kinetics of lemborexant to orexin receptors might affect lemborexant’s capacity to help with enhancements in sleep beginning and upkeep with very little early morning recurring results. It has actually been authorized for the treatment of sleeping disorders in more than 25 nations consisting of Japan, the United States, Canada, Australia and nations in Asia.

1. Ferrie JE, et al. Sleep public health– a quickly growing field. Int J Epidemiol. 2011; 40( 6 ):1431– 1437.
2. Roth T. Insomnia: meaning, occurrence, etiology and repercussions. J Clin Sleep Med. 2007; 3(5 Suppl): S7– S10.
3. Cao X-L, et al. The occurrence of sleeping disorders in the basic population in China: A meta-analysis. PLoS ONE 2017,12( 2 ): e0170772.
4. Internal price quote

Media Inquiries:

Public Relations Department,
Eisai Co., Ltd.
+81-( 0) 3-3817-5120

Copyright © 2025 JCN Newswire. All rights scheduled. A department of Japan Corporate News Network.